Research programme: Alzheimer's disease antibody therapeutics - ProbiodrugAlternative Names: anti-pGlu3-Abeta monoclonal antibody - Probiodrug; PBD-C06; pGlu-specific mAb - Probiodrug
Latest Information Update: 26 Jul 2014
At a glance
- Originator Probiodrug
- Class Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease